Latest Breaking News On - Using imprint - Page 1 : comparemela.com

Data from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy.

United statesSan franciscoDenisem wolfAmerican association for cancer researchMsc of the university californiaUniversity of alabama at birminghamUsing imprintAmerican associationCancer researchPredictive biomarkersImmune expressionPatients withRitu anejaPredict long term